Harveer S Dev - School of Clinical Medicine, University of Cambridge

基本信息

Career Trajectory

Bio

I am a CRUK Clinical Lecturer, with a research interest in genome stability and prostate cancer. Mutations in genes like BRCA1 contribute to the development of various diseases including prostate cancer, but these also generate therapeutic vulnerabilities. My aim is to better understand these pathways in cancer, and how they relate to disease progression and treatment response. This will allow us to better diagnose and stratify patients to individualised therapies at earlier stages of disease

Research Interests

Papers共 41 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Androgen Receptor Inhibition Extends PARP Inhibitor Activity in Prostate Cancer Models Beyond BRCA Mutations and Defects in Homologous Recombination Repair

Giuditta Illuzzi,Alessandro Galbiati,Anna D Staniszewska, Robert Hanson,Chrysiis Michaloglou, Sophie Cooke, Karolina Uznanska, Maja Bialecka,Kamil Solarczyk,Harveer S Dev,Charles E Massie,Mark R Albertella,Elisabetta Leo,Josep V Forment,Mark J O'Connor

biorxiv（2025）

Cited0Views0Bibtex

Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer

Harveer Dev,Mark Linch,Krishna Narahari, Toby Milne-Clark, Melissa Cheung, Anne Warren, Alopa Malaviya,Vincent Gnanapragasam,Tatiana Hernandez, Nicholas Bullock,Andrea Machin,Alimu Dayimu, Tamsin Robb, Elizabeth Cromwell,Alex Freeman,Elizabeth A Harrington, Niedzika Camacho, Silvia Glont, Massimo Squatrito, Asaf Rotem,Luiza Moore, Robert Hanson, Marc Dodd,Shubha Anand,Howard Kynaston, Greg Shaw,Nimish Shah,Simon Pacey

Clinical cancer research an official journal of the American Association for Cancer Researchno. 12 (2025): 2347-2357

Cited0Views0WOSBibtex

Abstract A021: Pre and Post Treatment Transcriptomic Analysis Provide New Insights on the Mechanisms Underlying the Efficacy of PARPi and Androgen Blockage in Prostate Cancer

Ana Filipa Palma dos Reis, Toby Milne-Clark,Amit Dipak Amin, Liliya Nazlamova,Simon Pacey,Harveer Dev

CANCER RESEARCHno. 1 (2024)

Cited0Views0Bibtex

Ultrasensitive Detection of Circulating Tumour DNA Enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer

European urologyno. 4 (2024): 407-410

Cited3Views0WOSBibtex

Trifecta Outcomes of Robot-Assisted Radical Prostatectomy: the “balancing Act” of Achieving Cancer Control and Minimizing Collateral Damage

Prasanna Sooriakumaran,Harveer S. Dev,Erica Huang,Joshua Tran,Rafael Gevorkyan,Thomas E. Ahlering,Peter Wiklund

Urinary Continence and Sexual Function After Robotic Prostatectomy, Radiation, and Novel Therapiespp.97-113, (2024)

Cited1Views0Bibtex

Prostate Cancer Detection Through Unbiased Capture of Methylated Cell-Free DNA

Ermira Lleshi, Toby Milne-Clark, Henson Lee Yu,Henno W. Martin, Robert Hanson,Radoslaw Lach,Sabrina H. Rossi,Anja Lisa Riediger,Magdalena Goertz,Holger Sueltmann,Andrew Flewitt,Andy G. Lynch,Vincent J. Gnanapragasam,Charlie E. Massie,Harveer S. Dev

iScienceno. 7 (2024): 110330-110330

Cited0Views0WOSBibtex

Early Detection Assay Using Ctdna Methylation for Hard-to-detect Cases Including Prostate and Renal Cancer

H. S. Dev, R. Lach,G. Park, R. Hanson, H. Martin,E. Lleshi,S. Rossi,A. Redmond,V. Gnanapragasam,R. Fitzgerald,G. Stewart,C. Massie

EUROPEAN UROLOGY（2023）

Cited0Views0Bibtex

Abstract B061: Updated Analysis of “CANCAP03” – A Study into the Pharmacodynamic Biomarker Effects of Olaparib (PARP Inhibitor) ± Degarelix (gnrh Antagonist) Given Prior to Radical Prostatectomy

Harveer Dev,Mark Linch,Howard Kynaston,Greg Shaw,Krishna Narahari,Tatiana Hernández,Anne Warren, Alopa Malaviya,Vincent Gnanapragasam,Elizabeth Harrington,Niedzica Camacho, Silvia Glont, Massimo Sqautrito,Joshua Armenia,Luiza Moore, Robert Hanson, Toby Milne-Clarke,Shubha Anand,Charlie Massie,Nimish Shah,Simon Pacey

Cancer Researchno. 11_Supplement (2023)

Cited0Views0Bibtex

Updated Analysis of "CANCAP03" - A Study into the Pharmacodynamic Biomarker Effects of Olaparib (PARP Inhibitor) ± Degarelix (gnrh Antagonist) Given Prior to Radical Prostatectomy

Harveer Dev,Mark Linch,Howard Kynaston,Greg Shaw,Krishna Narahari,Tatiana Hernandez,Anne Warren, Alopa Malaviya,Elizabeth Harrington, Silvia Glont, Massimo Sqautrito,Joshua Armenia,Luiza Moore, Robert Hanson, Toby Milne-Clarke,Shubha Anand,Charlie Massie,Nimish Shah,Simon Pacey

CANCER RESEARCHno. 11 (2023)

Cited2Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn